CENTESSA PHARMACEUTICALS PLC - AMERICAN DEPOSITARY

Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

06 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

26 Jan 2023 08:08:14 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

10 Dec 2022 14:30:29 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson

30 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022

10 Nov 2022 06:00:04 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting 

03 Nov 2022 08:04:09 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

31 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)

20 Sep 2022 07:34:08 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B

14 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index

12 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

29 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874

10 Aug 2022 05:30:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs

25 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

01 Jul 2022 07:40:42 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

06 Jun 2022 07:00:02 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting

05 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

02 Jun 2022 05:29:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates

16 May 2022 06:00:01 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update

30 Mar 2022 15:01:00 By Nasdaq GlobeNewswire